Anti-Spike NTD antibody (4A8) from ProteoGenix; catalogue PTXCOV-A548; research use only.
Know who made it. See the evidence. Buy through one marketplace.
SARS-CoV-2, the etiological agent of COVID-19 pneumonia, initiates the infection by binding the ACE2 (angiotensin-converting enzyme 2) receptor enriched on the surface of human epithelial cells. This initial interaction is mediated by the spike glycoprotein of the new coronavirus which, subsequently, undergoes proteolytic cleavage and rearrangement to form the membrane fusion complex. Due to its vital role in infection, the spike is currently the most biologically relevant target for the development of therapeutic antibodies and vaccines.
The anti-spike NTD antibody is a fully human IgG immunoglobulin recovered from the convalescent plasma of COVID-19 patients. The antibody was isolated by sorting peripheral blood mononuclear cells (PBMCs) to recover anti-SARS-CoV-2 antibody-secreting subpopulations. Antibody genes were further amplified from single cells (single-cell PCR) and the candidate antibodies were recombinantly expressed in Chinese hamster ovary (CHO) cell lines.
This specific anti-NTD antibody was shown to bind with high affinity to the S1 subunit of the spike glycoprotein of SARS-CoV-2. However, unlike previously described in prior studies with COVID-19 patients, this antibody targets the N-terminal domain (NTD) of the spike protein and not the receptor-binding domain (RBD), as expected.
Interestingly, despite recognizing an epitope outside the infection-initiating domain, the NTD antibody displayed a strong neutralizing activity in tests with authentic and pseudotyped SARS-CoV-2. Further crystallographic studies revealed that the antibody may allow the binding of the virus to its human receptor, ACE2, but prevent the conformational change of the spike, essential for membrane fusion.
The behavior has been observed before in studies with MERS-CoV, suggesting that a variety of different mechanisms are responsible for the efficient neutralization of these viruses in the human organism. Thus, the anti-spike NTD antibody has therapeutic value due to its SARS-CoV-2 neutralizing activity. However, it is also a valuable reagent for research to further elucidate the infection mechanism of the new coronavirus.
ProteoGenix catalogue number PTXCOV-A548. For research use only.
Target: Spike NTD domain; Host: Mouse; Clonality: Monoclonal Antibody; Expression system: Mammalian; Purity: 85%; Molecular weight: 150kDa; Buffer: PBS, pH7,5; Reactivity: SARS-CoV-2; Applications: ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
